GCM
XLO icon

Ghisallo Capital Management’s Xilio Therapeutics XLO Stock Holding History

Ghisallo Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,800
Closed -$116K – 373
2026
Q1 		$116K Sell
13,800
-65,716
-83% -$538K ﹤0.01% 271
2025
Q4 		$713K Buy
+79,516
New +$835K 0.03% 189
2025
Q3 		– Sell
-95,214
Closed -$906K – 258
2025
Q2 		$906K Buy
+95,214
New +$1.01M 0.02% 170
2022
Q1 		– Sell
-2,143
Closed -$480K – 414
2021
Q4 		$480K Buy
+2,143
New +$511K 0.02% 414

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ghisallo Capital Management's XLO Position: Q2 2026 in Review

Ghisallo Capital Management sold out of Xilio Therapeutics (XLO) in Q2 2026, closing a stake of 13,800 shares — an estimated $116K sold.

Ghisallo Capital Management first reported a position in XLO in Q4 2021 and held it in 4 quarters. The position peaked at $906K in Q2 2025. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Ghisallo Capital Management reported no remaining Xilio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ghisallo Capital Management sold 13,800 Xilio Therapeutics shares in Q2 2026, an estimated $116K.
  • Ghisallo Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ghisallo Capital Management's Xilio Therapeutics position peaked at $906K in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.